

Antonella Chillemi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5739919/publications.pdf>

Version: 2024-02-01

19
papers

1,163
citations

623734

14
h-index

794594

19
g-index

19
all docs

19
docs citations

19
times ranked

2013
citing authors

#	ARTICLE	IF	CITATIONS
1	CD38 and CD157: A long journey from activation markers to multifunctional molecules. <i>Cytometry Part B - Clinical Cytometry</i> , 2013, 84B, 207-217.	1.5	236
2	A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. <i>Oncoimmunology</i> , 2013, 2, e26246.	4.6	216
3	CD56brightCD16 ^{hi} NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4 ⁺ T Cell Proliferation. <i>Journal of Immunology</i> , 2015, 195, 965-972.	0.8	111
4	NAD ⁺ -Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model. <i>Cells</i> , 2015, 4, 520-537.	4.1	99
5	Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates With Progression of Human Myeloma. <i>Molecular Medicine</i> , 2016, 22, 694-704.	4.4	81
6	A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation. <i>Oncotarget</i> , 2015, 6, 25602-25618.	1.8	79
7	Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule. <i>Molecular Medicine</i> , 2013, 19, 99-108.	4.4	58
8	Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche. <i>Frontiers in Immunology</i> , 2017, 8, 305.	4.8	52
9	Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation. <i>Oncotarget</i> , 2017, 8, 56598-56611.	1.8	52
10	Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. <i>Annals of the New York Academy of Sciences</i> , 2015, 1335, 10-22.	3.8	47
11	CD38 and bone marrow microenvironment. <i>Frontiers in Bioscience - Landmark</i> , 2014, 19, 152.	3.0	26
12	Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins. <i>Molecular Therapy</i> , 2016, 24, 1760-1770.	8.2	24
13	The hidden life of NAD ⁺ -consuming ectoenzymes in the endocrine system. <i>Journal of Molecular Endocrinology</i> , 2010, 45, 183-191.	2.5	18
14	Generation and Characterization of Microvesicles after Daratumumab Interaction with Myeloma Cells. <i>Blood</i> , 2015, 126, 1849-1849.	1.4	16
15	Antibody mimicry, receptors and clinical applications. <i>Human Antibodies</i> , 2017, 25, 75-85.	1.5	15
16	Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors. <i>Frontiers in Pharmacology</i> , 2018, 9, 196.	3.5	15
17	Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells. <i>Molecular Medicine</i> , 2017, 23, 235-246.	4.4	9
18	CD38 and Antibody Therapy: What Can Basic Science Add?. <i>Blood</i> , 2016, 128, SCI-36-SCI-36.	1.4	8

#	ARTICLE	IF	CITATIONS
19	Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity. <i>Blood</i> , 2015, 126, 2959-2959.	1.4	1